About Brii Biosciences
Brii Biosciences is a company based in San Francisco (United States) founded in 2018 by Zhi Hong.. Brii Biosciences has raised $415 million across 3 funding rounds from investors including Arch Venture Partners, Invesco and Lake Bleu Capital. The company has 98 employees as of December 31, 2024. Brii Biosciences operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter San Francisco, United States
- Employees 98 as on 31 Dec, 2024
- Founders Zhi Hong
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Brii Biosciences Limited
-
Annual Revenue
$0 (USD)-100as on Dec 31, 2024
-
Net Profit
$-70.94 M (USD)-185.2as on Dec 31, 2024
-
EBITDA
$-62.11 M (USD)25.29as on Dec 31, 2024
-
Total Equity Funding
$415 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Sep 07, 2021
-
Investors
Arch Venture Partners
& 8 more
-
Employee Count
98
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Brii Biosciences
Brii Biosciences is a publicly listed company on the HKEX with ticker symbol 2137 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Brii Biosciences
Brii Biosciences has successfully raised a total of $415M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $100.0M
-
First Round
First Round
(25 May 2018)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Post-IPO - Brii Biosciences | Valuation |
investors |
|
| Mar, 2021 | Amount | Series D - Brii Biosciences | Valuation | Invesco | |
| May, 2018 | Amount | Series D - Brii Biosciences | Valuation | Yunfeng Capital , Arch Venture Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Brii Biosciences
Brii Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Arch Venture Partners, Invesco and Lake Bleu Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Founded Year | Domain | Location | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Brii Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Brii Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Brii Biosciences Comparisons
Competitors of Brii Biosciences
Brii Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Brii Biosciences
Frequently Asked Questions about Brii Biosciences
When was Brii Biosciences founded?
Brii Biosciences was founded in 2018.
Where is Brii Biosciences located?
Brii Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Brii Biosciences?
Zhi Hong is the current CEO of Brii Biosciences. They have also founded this company.
Is Brii Biosciences a funded company?
Brii Biosciences is a funded company, having raised a total of $415M across 3 funding rounds to date. The company's 1st funding round was a Series D of $260M, raised on May 25, 2018.
How many employees does Brii Biosciences have?
As of Dec 31, 2024, the latest employee count at Brii Biosciences is 98.
What does Brii Biosciences do?
Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).
Who are the top competitors of Brii Biosciences?
Brii Biosciences's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Is Brii Biosciences publicly traded?
Yes, Brii Biosciences is publicly traded on HKEX under the ticker symbol 2137.
Who are Brii Biosciences's investors?
Brii Biosciences has 9 investors. Key investors include Arch Venture Partners, Invesco, Lake Bleu Capital, GIC, and Yunfeng Capital.
What is Brii Biosciences's ticker symbol?
The ticker symbol of Brii Biosciences is 2137 on HKEX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.